NO20022442L - Legemidler for sykdommer i forbindelse med reduksjon i benmasse - Google Patents

Legemidler for sykdommer i forbindelse med reduksjon i benmasse

Info

Publication number
NO20022442L
NO20022442L NO20022442A NO20022442A NO20022442L NO 20022442 L NO20022442 L NO 20022442L NO 20022442 A NO20022442 A NO 20022442A NO 20022442 A NO20022442 A NO 20022442A NO 20022442 L NO20022442 L NO 20022442L
Authority
NO
Norway
Prior art keywords
bone mass
medicines
reduction
diseases related
agonist
Prior art date
Application number
NO20022442A
Other languages
English (en)
Other versions
NO20022442D0 (no
Inventor
Takayuki Maruyama
Masaharu Tanaka
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20022442D0 publication Critical patent/NO20022442D0/no
Publication of NO20022442L publication Critical patent/NO20022442L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20022442A 1999-11-24 2002-05-23 Legemidler for sykdommer i forbindelse med reduksjon i benmasse NO20022442L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP33349099 1999-11-24
JP2000056534 2000-03-01
JP2000119188 2000-04-20
PCT/JP2000/008235 WO2001037877A1 (fr) 1999-11-24 2000-11-22 Medicaments pour des affections liees a la perte de masse osseuse

Publications (2)

Publication Number Publication Date
NO20022442D0 NO20022442D0 (no) 2002-05-23
NO20022442L true NO20022442L (no) 2002-07-24

Family

ID=27340604

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022442A NO20022442L (no) 1999-11-24 2002-05-23 Legemidler for sykdommer i forbindelse med reduksjon i benmasse

Country Status (16)

Country Link
US (1) US6891062B2 (no)
EP (1) EP1232757B1 (no)
JP (1) JP3705360B2 (no)
KR (1) KR100654653B1 (no)
CN (1) CN1262309C (no)
AT (1) ATE452640T1 (no)
AU (1) AU783939B2 (no)
CA (1) CA2391526A1 (no)
DE (1) DE60043587D1 (no)
ES (1) ES2337333T3 (no)
HU (1) HUP0203590A3 (no)
MX (1) MXPA02005173A (no)
NO (1) NO20022442L (no)
NZ (1) NZ519101A (no)
TW (1) TWI247606B (no)
WO (1) WO2001037877A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408961B1 (en) * 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
KR100826866B1 (ko) * 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
JPWO2003041717A1 (ja) * 2001-11-12 2005-03-03 小野薬品工業株式会社 プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤
AU2003233297A1 (en) * 2002-05-23 2003-12-12 Theratechnologies Inc Antagonistic peptides of prostaglandin e2 receptor subtype ep4
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2006075690A1 (ja) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. 安定な医薬組成物
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
JPWO2006118173A1 (ja) 2005-04-28 2008-12-18 小野薬品工業株式会社 経皮吸収製剤
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
CN101495623B (zh) 2006-03-24 2013-09-11 儿童医疗中心有限公司 调节造血干细胞生长的方法
US9402852B2 (en) 2006-10-20 2016-08-02 Children's Medical Center Corporation Method to enhance tissue regeneration
KR20090075864A (ko) 2006-10-26 2009-07-09 오노 야꾸힝 고교 가부시키가이샤 첨부제
EP2147672A4 (en) * 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
US20110206781A1 (en) * 2008-05-28 2011-08-25 Zon Leonard I Method to modulate hematopoietic stem cell growth
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
EP2454227B1 (en) 2009-07-13 2020-08-19 Patheon API Services Inc. Synthesis of prostanoids
WO2013082241A2 (en) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Improved methods of treating ischemia
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
EP3176162B1 (en) 2012-07-19 2020-05-27 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
EP2968416A4 (en) 2013-03-15 2016-08-17 Fate Therapeutics Inc BIOLOGICAL ACTIVITY TESTING OF CELLS FOR A THERAPEUTIC POTENTIAL
SG11201507470WA (en) 2013-03-15 2015-10-29 Cayman Chemical Co Inc Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、***和组合物
KR102311896B1 (ko) 2013-09-30 2021-10-14 패턴 에이피아이 서비시즈 인코포레이티드 복분해를 사용하는 프로스타글란딘 및 프로스타글란딘 중간체의 합성 경로
MX2018003462A (es) 2015-09-22 2018-09-06 Graybug Vision Inc Compuestos y composiciones para el tratamiento de trastornos oculares.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130333A0 (en) * 1996-12-20 2000-06-01 Pfizer Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists
JPH10265454A (ja) * 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation

Also Published As

Publication number Publication date
CN1424918A (zh) 2003-06-18
US6891062B2 (en) 2005-05-10
ATE452640T1 (de) 2010-01-15
AU1548501A (en) 2001-06-04
HUP0203590A3 (en) 2006-07-28
AU783939B2 (en) 2006-01-05
CA2391526A1 (en) 2001-05-31
NO20022442D0 (no) 2002-05-23
CN1262309C (zh) 2006-07-05
HUP0203590A2 (hu) 2003-03-28
KR20020059774A (ko) 2002-07-13
NZ519101A (en) 2004-04-30
JP3705360B2 (ja) 2005-10-12
TWI247606B (en) 2006-01-21
KR100654653B1 (ko) 2006-12-07
EP1232757B1 (en) 2009-12-23
DE60043587D1 (de) 2010-02-04
EP1232757A1 (en) 2002-08-21
ES2337333T3 (es) 2010-04-23
WO2001037877A1 (fr) 2001-05-31
US20040209848A1 (en) 2004-10-21
EP1232757A4 (en) 2004-06-16
MXPA02005173A (es) 2004-02-26

Similar Documents

Publication Publication Date Title
NO20022442D0 (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
NZ514574A (en) Novel method of treatment
TW200505901A (en) Muscarinic agonists
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
HUP0600140A2 (en) Prostaglandine derivatives for the treatment of diseases with bone mass loss having ep4 agonist activity and pharmaceutical compositions thereof
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
BR0315580A (pt) Derivados de metileno uréia
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
DE50012571D1 (de) Biotin enthaltende galenische formulierung
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
WO2001074396A8 (en) Composition and method for promoting oral health
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
HUP9802716A2 (hu) Fájdalomcsillapító gyógyszerkombináció
DK1209166T3 (da) Hidtil ukendte A-500 359-derivater
SE0000303D0 (sv) Novel compounds
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
SE0203817D0 (sv) New composition
WO2001007029A3 (en) Substituted guanidines and the use thereof
EP1652525A4 (en) ANTI-CORONAVIRUS MEDICINE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application